CreoSG Secures South Korean Patent for Recombinant VSV-Based COVID-19 Vaccine

CreoSG has secured a South Korean patent for COVID-19 vaccine technology using its proprietary recombinant VSV (Vesicular Stomatitis Virus) platform. The company plans to strengthen the foundation for future vaccine research and development and commercialization by expanding its intellectual property rights for a vaccine platform that can be applied to various infectious diseases.

CreoSG announced on October 22 that it had obtained a South Korean patent for COVID-19 vaccine technology using a recombinant VSV vector system.

The patented technology uses SUV-MAP, CreoSG's recombinant VSV-based vaccine platform. SUV-MAP is a vaccine development platform designed to attenuate the VSV vector through genetic recombination to improve safety, then insert the target virus's antigen gene to induce an immune response.

The COVID-19 vaccine covered by the patent uses an antigen gene from the SARS-CoV-2 virus. The approach involves inserting a target antigen gene into the platform to create a recombinant virus and induce an immune response. The company said the technology could serve as a technical foundation for developing and commercializing vaccine candidates in the future.

A key feature of SUV-MAP is that a single platform can be applied to various infectious diseases. The company said that because the antigen gene can be changed according to the target virus, the platform is scalable and can address not only existing infectious diseases but also new variants and emerging viruses.

In addition, SUV-MAP is designed to produce recombinant viruses carrying a target antigen gene and then use cultured cells to manufacture them for use as vaccine materials. The company expects the platform to contribute to shorter development timelines and more efficient production processes, as it can support the development of vaccine candidates for multiple infectious diseases.

CreoSG previously obtained patents in Saudi Arabia and Canada for MERS vaccine technology using SUV-MAP. With the South Korean patent for its COVID-19 vaccine, the company has further expanded its intellectual property rights for recombinant VSV vaccine technology that can be applied to coronavirus-related infectious diseases.

Using its proprietary recombinant VSV vector system technology, the company is pursuing vaccine technology development and individual patent acquisitions for various infectious diseases, including Zika, MERS, COVID-19, Hantavirus, and severe fever with thrombocytopenia syndrome (SFTS).

A CreoSG representative said, "Obtaining a South Korean patent for this COVID-19 vaccine is significant because it further strengthens the intellectual property competitiveness of the recombinant VSV vector technology that we have secured and developed over many years. Together with the MERS vaccine patents we previously obtained, this patent is expected to expand the SUV-MAP platform's potential to address various infectious diseases and provide an important foundation for pursuing domestic and international R&D collaborations and vaccine commercialization."

The representative added, "The COVID-19 pandemic underscored the importance of vaccine platform technologies that can respond rapidly to emerging infectious diseases. Building on SUV-MAP's technical scalability and potential applications, we plan to continue developing vaccines for a range of infectious diseases."

CreoSG plans to continue strengthening the technical competitiveness and intellectual property rights of its vaccine platform, centered on SUV-MAP, and expand its R&D and commercialization opportunities through strategic partnerships in South Korea and abroad.

This content was produced with the assistance of AI translation services.